Lian J-H, Guo L, Hu W-R, Wu G-L, Ji W, Gong B-Q
East China University of Science and Technology, Shanghai, P.R. China.
Exp Clin Endocrinol Diabetes. 2007 Jan;115(1):24-8. doi: 10.1055/s-2007-949590.
Protein Tyrosine Phosphatase 1B (PTP1B), an important negative regulator of insulin signaling, is thought to be an attractive therapeutic target for insulin resistance and type 2 diabetes. For the aim of screening PTP1B expression down-regulators, we established the drug screening cellular model based on transcriptional regulation of PTP1B. In this study, the promoter sequences of PTP1B were cloned into pGL3B-neo vector containing luciferase gene and neomycin resistance gene. The recombinant reporter gene vector pGL3B-neo /PTP1B was transfected into CV1 cells and therefore stable cell line, namely SPTP1B, was obtained. With the cell-based reporter gene assay, we detected more than one hundred compounds in microtiter wells. In the screening process, the compound CM107 which had extracted from the traditional Chinese medicinal herbs was identified to repress the activity of PTP1B promoter significantly in mode of dose-dependence.
蛋白酪氨酸磷酸酶1B(PTP1B)是胰岛素信号的重要负调节因子,被认为是胰岛素抵抗和2型糖尿病的一个有吸引力的治疗靶点。为了筛选PTP1B表达下调剂,我们基于PTP1B的转录调控建立了药物筛选细胞模型。在本研究中,将PTP1B的启动子序列克隆到含有荧光素酶基因和新霉素抗性基因的pGL3B-neo载体中。将重组报告基因载体pGL3B-neo /PTP1B转染到CV1细胞中,从而获得稳定细胞系,即SPTP1B。通过基于细胞的报告基因检测,我们在微孔板中检测了一百多种化合物。在筛选过程中,从中药中提取的化合物CM107被鉴定为以剂量依赖性方式显著抑制PTP1B启动子的活性。